Roquefort Therapeutics plc (LON:ROQ – Get Free Report) shares were down 6.9% during mid-day trading on Friday . The stock traded as low as GBX 3.55 ($0.04) and last traded at GBX 3.68 ($0.05). Approximately 1,670,536 shares traded hands during trading, an increase of 25% from the average daily volume of 1,334,411 shares. The stock had previously closed at GBX 3.95 ($0.05).
Roquefort Therapeutics Stock Performance
The business’s fifty day moving average price is GBX 4.05 and its 200-day moving average price is GBX 4.05. The stock has a market cap of £4.55 million, a PE ratio of -352.50 and a beta of 0.05. The company has a debt-to-equity ratio of 12.37, a quick ratio of 3.07 and a current ratio of 0.79.
About Roquefort Therapeutics
Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.
Read More
- Five stocks we like better than Roquefort Therapeutics
- Short Selling: How to Short a Stock
- Bloom Energy: Powering the Future With Decentralized Energy
- How to invest in marijuana stocks in 7 steps
- Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Why Traders Are Buying the Dip on Johnson & Johnson Stock
Receive News & Ratings for Roquefort Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roquefort Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
